Multipotent mesenchymal stromal cells as treatment for poor graft function after allogeneic hematopoietic cell transplantation: A multicenter prospective analysis
Multipotent mesenchymal stromal cells as treatment for poor graft function after allogeneic hematopoietic cell transplantation: A multicenter prospective analysis
Publication date :
2023
Journal title :
Frontiers in Immunology
eISSN :
1664-3224
Publisher :
Frontiers Research Foundation, Lausanne, Switzerland
Snowden JA Sánchez-Ortega I Corbacioglu S Basak GW Chabannon C de la Camara R et al. Indications for haematopoietic cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2022. Bone Marrow Transplant. (2022) 57(8):1217–39. doi: 10.1038/s41409-022-01691-w
Zhao Y Gao F Shi J Luo Y Tan Y Lai X et al. Incidence, risk factors, and outcomes of primary poor graft function after allogeneic hematopoietic stem cell transplantation. Biol Blood marrow Transplant J Am Soc Blood Marrow Transplant. (2019) 25(9):1898–907. doi: 10.1016/j.bbmt.2019.05.036
Sun YQ He GL Chang YJ Xu LP Zhang XH Han W et al. The incidence, risk factors, and outcomes of primary poor graft function after unmanipulated haploidentical stem cell transplantation. Ann Hematol (2015) 94(10):1699–705. doi: 10.1007/s00277-015-2440-x
Man Y Lu Z Yao X Gong Y Yang T Wang Y. Recent advancements in poor graft function following hematopoietic stem cell transplantation. Front Immunol (2022) 13:911174. doi: 10.3389/fimmu.2022.911174
Prabahran A Koldej R Chee L Ritchie D. Clinical features, pathophysiology, and therapy of poor graft function post-allogeneic stem cell transplantation. Blood Adv (2022) 6(6):1947–59. doi: 10.1182/bloodadvances.2021004537
Cuadrado MM Szydlo RM Watts M Patel N Renshaw H Dorman J et al. Predictors of recovery following allogeneic CD34+-selected cell infusion without conditioning to correct poor graft function. Haematologica (2020) 105(11):2639–46.
Kharfan-Dabaja MA Kumar A Ayala E Aljurf M Nishihori T Marsh R et al. Standardizing definitions of hematopoietic recovery, graft rejection, graft failure, poor graft function, and donor chimerism in allogeneic hematopoietic cell transplantation: A report on behalf of the American society for transplantation and cellular Th. In: Transplantation and cellular therapy, vol. 27. United States (2021). p. 642–9.
Prabahran A Koldej R Chee L Wong E Ritchie D. Evaluation of risk factors for and subsequent mortality from poor graft function (PGF) post allogeneic stem cell transplantation. Leuk Lymphoma. (2021) 62(6):1482–9. doi: 10.1080/10428194.2021.1872072
Mahat U Rotz SJ Hanna R. Use of thrombopoietin receptor agonists in prolonged thrombocytopenia after hematopoietic stem cell transplantation. Biol Blood marrow Transplant J Am Soc Blood Marrow Transplant. (2020) 26(3):e65–73. doi: 10.1016/j.bbmt.2019.12.003
Shahzad M Siddiqui RS Anwar I Chaudhary SG Ali T Naseem M et al. Outcomes with CD34-selected stem cell boost for poor graft function after allogeneic hematopoietic stem cell transplantation: A systematic review and meta-analysis. Transplant Cell Ther (2021) 27(10):877.e1–8. doi: 10.1016/j.jtct.2021.07.012
Kong Y Wang YT Hu Y Han W Chang YJ Zhang XH et al. The bone marrow microenvironment is similarly impaired in allogeneic hematopoietic stem cell transplantation patients with early and late poor graft function. Bone Marrow Transplant. (2016) 51(2):249–55. doi: 10.1038/bmt.2015.229
Kong Y Chang YJ Wang YZ Chen YH Han W Wang Y et al. Association of an impaired bone marrow microenvironment with secondary poor graft function after allogeneic hematopoietic stem cell transplantation. Biol Blood marrow Transplant J Am Soc Blood Marrow Transplant. (2013) 19(10):1465–73. doi: 10.1016/j.bbmt.2013.07.014
Kong Y. Poor graft function after allogeneic hematopoietic stem cell transplantation-an old complication with new insights(☆). Semin Hematol (2019) 56(3):215–20. doi: 10.1053/j.seminhematol.2018.08.004
Song Y Zhao HY Lyu ZS Cao XN Shi MM Wen Q et al. Dysfunctional bone marrow mesenchymal stem cells in patients with poor graft function after allogeneic hematopoietic stem cell transplantation. Biol Blood marrow Transplant J Am Soc Blood Marrow Transplant. (2018) 24(10):1981–9. doi: 10.1016/j.bbmt.2018.06.021
Crippa S Santi L Berti M De Ponti G Bernardo ME. Role of ex vivo expanded mesenchymal stromal cells in determining hematopoietic stem cell transplantation outcome. Front Cell Dev Biol (2021) 9:663316. doi: 10.3389/fcell.2021.663316
Song N Scholtemeijer M Shah K. Mesenchymal stem cell immunomodulation: Mechanisms and therapeutic potential. Trends Pharmacol Sci (2020) 41(9):653–64. doi: 10.1016/j.tips.2020.06.009
Ball LM Bernardo ME Roelofs H Lankester A Cometa A Egeler RM et al. Cotransplantation of ex vivo expanded mesenchymal stem cells accelerates lymphocyte recovery and may reduce the risk of graft failure in haploidentical hematopoietic stem-cell transplantation. Blood (2007) 110(7):2764–7. doi: 10.1182/blood-2007-04-087056
Li T Luo C Zhang J Wei L Sun W Xie Q et al. Efficacy and safety of mesenchymal stem cells co-infusion in allogeneic hematopoietic stem cell transplantation: a systematic review and meta-analysis. Stem Cell Res Ther (2021) 12(1):246. doi: 10.1186/s13287-020-02064-0
Carrancio S Romo C Ramos T Lopez-Holgado N Muntion S Prins HJ et al. Effects of MSC coadministration and route of delivery on cord blood hematopoietic stem cell engraftment. Cell Transplant. (2013) 22(7):1171–83. doi: 10.3727/096368912X657431
Preciado S Muntión S Sánchez-Guijo F. Improving hematopoietic engraftment: Potential role of mesenchymal stromal cell-derived extracellular vesicles. Stem Cells (2021) 39(1):26–32. doi: 10.1002/stem.3278
Preciado S Sirerol-Piquer MS Muntión S Osugui L Martí-Chillón GJ Navarro-Bailón A et al. Co-Administration of human MSC overexpressing HIF-1α increases human CD34(+) cell engraftment in vivo. Stem Cell Res Ther (2021) 12(1):601.
Lechanteur C Briquet A Giet O Delloye O Baudoux E Beguin Y. Clinical-scale expansion of mesenchymal stromal cells: a large banking experience. J Transl Med [Internet]. (2016) 14(1):145. doi: 10.1186/s12967-016-0892-y
Servais S Baron F Lechanteur C Seidel L Selleslag D Maertens J et al. Infusion of bone marrow derived multipotent mesenchymal stromal cells for the treatment of steroid-refractory acute graftversus- host disease: A multicenter prospective study. Oncotarget (2018) 9(29). doi: 10.18632/oncotarget.25020
Lechanteur C Briquet A Bettonville V Baudoux E Beguin Y. MSC manufacturing for academic clinical trials: From a clinical-grade to a full GMP-compliant process. Cells (2021) 10(6). doi: 10.3390/cells10061320
Copelan E Casper JT Carter SL van Burik JAH Hurd D Mendizabal AM et al. A scheme for defining cause of death and its application in the T cell depletion trial. Biol Blood marrow Transplant J Am Soc Blood Marrow Transplant. (2007) 13(12):1469–76. doi: 10.1016/j.bbmt.2007.08.047
Filipovich AH Weisdorf D Pavletic S Socie G Wingard JR Lee SJ et al. National institutes of health consensus development project on criteria for clinical trials in chronic graft-versus-Host disease: I. diagnosis and staging working group report. Biol Blood Marrow Transplant [Internet]. (2005) 11(12):945–56. Available at: https://linkinghub.elsevier.com/retrieve/pii/S1083879105006312.
Przepiorka D Weisdorf D Martin P Klingemann HG Beatty P Hows J et al. Bone marrow transplant [Internet], vol. 15. (19941995). p. 825–8.
Servais S Lengline E Porcher R Carmagnat M Peffault de Latour R Robin M et al. Long-term immune reconstitution and infection burden after mismatched hematopoietic stem cell transplantation. Biol Blood Marrow Transplant [Internet] (2014) 20(4):507–17. Available at: http://linkinghub.elsevier.com/retrieve/pii/S1083879114000020.
Meuleman N Tondreau T Ahmad I Kwan J Crokaert F Delforge A et al. Infusion of mesenchymal stromal cells can aid hematopoietic recovery following allogeneic hematopoietic stem cell myeloablative transplant: a pilot study. Stem Cells Dev (2009) 18(9):1247–52. doi: 10.1089/scd.2009.0029
Sánchez-Guijo FM López-Villar O López-Anglada L Villarón EM Muntión S Díez-Campelo M et al. Allogeneic mesenchymal stem cell therapy for refractory cytopenias after hematopoietic stem cell transplantation. Transfusion (2012) 52(5):1086–91. doi: 10.1111/j.1537-2995.2011.03400.x
Liu X Wu M Peng Y Chen X Sun J Huang F et al. Improvement in poor graft function after allogeneic hematopoietic stem cell transplantation upon administration of mesenchymal stem cells from third-party donors: A pilot prospective study. Cell Transplant. (2014) 23(9):1087–98. doi: 10.3727/096368912X661319
Zhu L Liu J Kong P Gao S Wang L Liu H et al. Analysis of the efficacy and safety of avatrombopag combined with MSCs for the treatment of thrombocytopenia after allogeneic hematopoietic stem cell transplantation. Front Immunol (2022) 13:910893. doi: 10.3389/fimmu.2022.910893
Uria-Oficialdegui ML Alonso L Benitez-Carabante MI Renedo B Oliveras M Diaz-de-Heredia C. Use of eltrombopag for the treatment of poor graft function after hematopoietic stem cell transplantation in children. Pediatr Transplant. (2021) 25(4):e14010. doi: 10.1111/petr.14010
Peffault de Latour R Chevret S Ruggeri AL Suarez F Souchet L Michonneau D et al. Romiplostim in patients undergoing hematopoietic stem cell transplantation: results of a phase 1/2 multicenter trial. Vol. 135 Blood. United States; (2020) p:227–9.
Carreras E Dufour C Mohty M Kröger N. The EBMT handbook: Hematopoietic stem cell transplantation and cellular therapies. Cham, Switzerland: Springer N (2019).
McLornan DP Hernandez-Boluda JC Czerw T Cross N Joachim Deeg H Ditschkowski M et al. Allogeneic haematopoietic cell transplantation for myelofibrosis: proposed definitions and management strategies for graft failure, poor graft function and relapse: best practice recommendations of the EBMT chronic malignancies working party. Leukemia (2021) 35(9):2445–59. doi: 10.1038/s41375-021-01294-2
Yamazaki R Kuwana M Mori T Okazaki Y Kawakami Y Ikeda Y et al. Prolonged thrombocytopenia after allogeneic hematopoietic stem cell transplantation: Associations with impaired platelet production and increased platelet turnover. Bone Marrow Transplant. (2006) 38(5):377–84. doi: 10.1038/sj.bmt.1705444
Bolwell B Pohlman B Sobecks R Andresen S Brown S Rybicki L et al. Prognostic importance of the platelet count 100 days post allogeneic bone marrow transplant. Bone Marrow Transplant. (2004) 33(4):419–23. doi: 10.1038/sj.bmt.1704330
Alchalby H Yunus DR Zabelina T Ayuk F Kröger N. Incidence and risk factors of poor graft function after allogeneic stem cell transplantation for myelofibrosis. Bone Marrow Transplant. (2016) 51(9):1223–7. doi: 10.1038/bmt.2016.98
Reich-Slotky R Al-Mulla N Hafez R Segovia-Gomez J Goel R Mayer S et al. Poor graft function after T cell-depleted allogeneic hematopoietic stem cell transplant. Leuk Lymphoma. (2020) 61(12):2894–9. doi: 10.1080/10428194.2020.1789622
Baron F Lechanteur C Willems E Bruck F Baudoux E Seidel L et al. Cotransplantation of mesenchymal stem cells might prevent death from graft-versus-host disease (GVHD) without abrogating graft-versus-tumor effects after HLA-mismatched allogeneic transplantation following nonmyeloablative conditioning. Biol Blood marrow Transplant J Am Soc Blood Marrow Transplant. (2010) 16(6):838–47. doi: 10.1016/j.bbmt.2010.01.011
Grégoire C Layios N Lambermont B Lechanteur C Briquet A Bettonville V et al. Bone marrow-derived mesenchymal stromal cell therapy in severe COVID-19: Preliminary results of a phase I/II clinical trial. Front Immunol (2022) 13:932360. doi: 10.3389/fimmu.2022.932360
Moermans C Lechanteur C Baudoux E Giet O Henket M Seidel L et al. Impact of cotransplantation of mesenchymal stem cells on lung function after unrelated allogeneic hematopoietic stem cell transplantation following non-myeloablative conditioning. Transplant [Internet] (2014) 98(3):348–53. Available at: http://content.wkhealth.com/linkback/openurl?sid=WKPTLP:landingpage&an=00007890-201408150-00020.
Detry O Vandermeulen M Delbouille MH Somja J Bletard N Briquet A et al. Infusion of mesenchymal stromal cells after deceased liver transplantation: A phase I-II, open-label, clinical study. J Hepatol (2017) 67(1):47–55. doi: 10.1016/j.jhep.2017.03.001
Vandermeulen M Mohamed-Wais M Erpicum P Delbouille MH Lechanteur C Briquet A et al. Infusion of allogeneic mesenchymal stromal cells after liver transplantation: A 5-year follow-up. Liver Transplant Off Publ Am Assoc Study Liver Dis Int Liver Transplant Soc (2022) 28(4):636–46. doi: 10.1002/lt.26323
Thompson M Mei SHJ Wolfe D Champagne J Fergusson D Stewart DJ et al. Cell therapy with intravascular administration of mesenchymal stromal cells continues to appear safe: An updated systematic review and meta-analysis. EClinicalMedicine (2020) 19:100249. doi: 10.1016/j.eclinm.2019.100249
Grégoire C Ritacco C Hannon M Seidel L Delens L Belle L et al. Comparison of mesenchymal stromal cells from different origins for the treatment of graft-vs.-Host-Disease in a humanized mouse model. Front Immunol (2019) 10:619. doi: 10.3389/fimmu.2019.00619
Lalu MM McIntyre L Pugliese C Fergusson D Winston BW Marshall JC et al. Safety of cell therapy with mesenchymal stromal cells (SafeCell): A systematic review and meta-analysis of clinical trials. In: Beltrami AP, editor. PLoS one [Internet], vol. 7 (2012). Available at: http://dx.plos.org/10.1371/journal.pone.0047559.
Ringdén O Moll G Gustafsson B Sadeghi B. Mesenchymal stromal cells for enhancing hematopoietic engraftment and treatment of graft-Versus-Host disease, hemorrhages and acute respiratory distress syndrome. In: Fron Immunol (Switzerland) (2022) 13:839844.
Styczyński J Tridello G Koster L Iacobelli S van Biezen A van der Werf S et al. Death after hematopoietic stem cell transplantation: Changes over calendar year time, infections and associated factors. Bone Marrow Transplant. (2020) 55(1):126–36. doi: 10.1038/s41409-019-0624-z
